Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,995 JPY | -4.13% | +23.00% | +34.21% |
04-30 | Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis | CI |
04-30 | PeptiDream Inc. Announces Expansion of Peptide Discovery Collaboration with Novartis Pharma AG | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 36.74 and 28.33 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.21% | 1.69B | B- | ||
+8.64% | 105B | B+ | ||
-0.90% | 104B | B+ | ||
+5.44% | 22.94B | B | ||
-12.25% | 22.34B | B+ | ||
-6.31% | 19.25B | A- | ||
-37.08% | 17.08B | A- | ||
-8.69% | 16.96B | B | ||
+7.59% | 14.16B | C+ | ||
+38.96% | 12.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4587 Stock
- Ratings PeptiDream Inc.